Avantor, Inc.

NYSE:AVTR

Medical - Instruments & Supplies

Healthcare
$15.37 +0.69%

+$0.07 today

Market cap
$10.41B
Beta
0.96
P/E (TTM)
-11.7
EPS (TTM)
-$0.81
52W Low $7.27High $15.93

Volume 5.94M

Average 9.44M

AVTR Depreciation & Amortization

Non-cash expense that spreads the cost of physical and intangible assets over their useful lives.

Avantor, Inc.NYSE: AVTR

Depreciation & Amortization · Q2 FY2026 · quarter ended Jun 2026

Depreciation & amortization grows in line with its trailing trend

Q2 FY2026 depreciation & amortization of $105.6M rose 2.8% year over year, in line with the +3.1% change in trailing-twelve-month depreciation & amortization. Sequentially, it rose 0.6% from the prior quarter. Over 3 fiscal years it compounded at +0.4% a year.

Context

  • Depreciation & amortization amounted to 6.3% of revenue in FY2025, up 0.3 pp from a year earlier.
  • Depreciation & amortization increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from +2.8% toward the trailing-twelve-month pace of +3.1%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2026
$105.6M+0.6% QoQ
Last fiscal yearDec 2025
$410.2M+1.2% YoY
LTMJun 2026
$418.4M+3.1% YoY
Depreciation & Amortization past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+2.8%——
1 year+1.2%——
3-year CAGR+0.4%——
5-year CAGR——
10-year CAGR——

Depreciation & Amortization history

USD · from the income statement

Latest · FY2025
410.2M USD
Year-over-year change
+1.2%
4-year CAGR
+2.0%

Depreciation & Amortization vs competitors

How AVTR compares with its peers on the latest reported figures

  • Peers report in different currencies, so depreciation & amortization is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +3.1% is the 2nd highest of 9, against a peer median of -21.8%.
  • Depreciation & amortization amounts to 6.4% of revenue for AVTR, versus a peer median of 7.5%.
AVTR Competitors
Depreciation & Amortization for AVTR and competitors
Company Period LTM YoY 3-year CAGR% of revenue
DHRDanaher CorporationLTM Sep 2026$1.91B USD-21.1%+4.7%7.5%
AVTRAvantor, Inc.LTM Jun 2026$418.4M USD+3.1%+0.4%6.4%
CRLCharles River Laboratories International, Inc.LTM Jun 2026$297.88M USD-30.8%+9.9%7.4%
WSTWest Pharmaceutical Services, Inc.LTM Jun 2026$180.8M USD+11.4%+12.4%5.4%
BIOBio-Rad Laboratories, Inc.LTM Jun 2026$127.6M USD-23.5%+6.4%4.9%
RGENRepligen CorporationLTM Jun 2026$97.31M USD-7.0%+19.4%12.4%
STVNStevanato Group S.p.A.LTM Jun 2026€95.21M EUR-22.5%+11.0%7.8%
AZTAAzenta, Inc.LTM Sep 2026$56.52M USD-7.7%—9.1%
BLFSBioLife Solutions, Inc.LTM Mar 2026$4.8M USD-38.2%-38.3%4.8%
Peer median (excluding AVTR) —-21.8%+9.9%7.5%

Competitors are the stored peer set for AVTR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue7.39B7.51B6.97B6.78B6.55B
Cost of Revenue4.88B4.91B4.6B4.5B4.41B
Gross Profit2.5B2.6B2.36B2.28B2.14B
Gross Margin33.9%34.6%33.9%33.6%32.7%
Research & Development00000
Selling, General & Admin1.53B1.47B1.51B1.64B1.6B
Operating Expenses1.53B1.47B1.67B1.19B2.39B
Depreciation & Amortization379.2M405.5M402.3M405.5M410.2M
EBITDA1.35B1.52B1.1B1.48B138.7M
EBITDA Margin18.3%20.3%15.8%21.8%2.1%
Operating Income972.2M1.13B696.4M1.08B(246.2M)
Operating Margin13.2%15.0%10.0%16.0%-3.8%
Interest Income00000
Interest Expense217.4M265.8M284.8M218.8M169.8M
Other Income / Expenses(219.2M)(279.1M)(285.9M)(230.9M)(195.1M)
Income Before Tax753M851.1M410.5M853.9M(441.3M)
Pre-Tax Margin10.2%11.3%5.9%12.6%-6.7%
Income Tax Expense180.4M164.6M89.4M142.4M88.9M
Net Income572.6M686.5M321.1M711.5M(530.2M)
Net Margin7.8%9.1%4.6%10.5%-8.1%
EPS (Basic)0.861.020.481.05(0.78)
EPS (Diluted)0.851.010.471.04(0.78)
Weighted Avg Shares590.5M650.9M675.6M680.3M678M
Weighted Avg Shares (Diluted)599.6M679.4M678.4M681.9M679.3M

Avantor, Inc.

NYSE:AVTR

Intrinsic Alpha fair value

Locked

Current Price

$15.37

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.